Abstract:A series of novel substituted triazines bearing a benzimidazole scaffold were designed and synthesized based on the structures of known anti-cancer agents, namely gedatolisib and alpelisib. All the target compounds were screened for inhibitory activity against PI3Kα and mTOR kinases. Notably, most analogs exhibited IC50 in the nanomolar range. Investigation of the isozyme selectivity indicated that the compounds exhibited remarkable inhibitory activity against PI3Kδ, especially compound 19f showed an IC50 value of 2.3 nM for PI3Kδ and moderate δ-isozyme selectivity over other class I PI3K isoforms and mTOR (with IC50 values of 14.6, 34.0, 849.0 and 15.4 nM for PI3Kα, β, γ and mTOR, respectively). An in vitro MTT assay was conducted to assess the antiproliferative and cytotoxic effects of the prepared analogs. It was revealed that the compounds displayed significant inhibitory activities against the HCT116 human colon cancer cell line. Compound 19i showed 4.7-fold higher potency than the positive control gedatolisib (0.3 vs. 1.4 μM, IC50 values). Phosphoblot studies demonstrated that 19c and 19i could significantly suppress the PI3K/Akt/mTOR signaling pathway at 10 μM. Moreover, analogs 19b, 19c and 19i displayed better stability in artificial gastric fluids than gedatolisib, while 19i was indicated not very stable in rat liver microsomes, and may occur phase I metabolic transformations.

Rational Design of a Novel 6H-Benzo[c]chromen Series As Selective PI3Kα Inhibitors

Rational Design of a Novel 6 H -Benzo[ c ]chromen Series as Selective PI3Kα Inhibitors

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Development of small-molecule inhibitors that target PI3K13

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugs

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Discovery of a Series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides As PI3K/mTOR Dual Inhibitors

Discovery and Synthesis of a Novel Series of Potent, Selective Inhibitors of the PI3Kα: 2-Alkyl-chromeno[4,3-c]pyrazol-4(2h)-one Derivatives.

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Novel 4-Acrylamido-quinoline Derivatives As Potent PI3K/mTOR Dual Inhibitors: the Design, Synthesis, and in Vitro and in Vivo Biological Evaluation.

Design And Synthesis Of A Novel Series Of N,4-Diphenylpyrimidin-2-Amine Derivatives As Potent And Selective Pi3k Gamma Inhibitors

Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies

Design, Synthesis and Biological Evaluation of Novel 4-Alkynyl-quinoline Derivatives As PI3K/mTOR Dual Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Selective PI3Kδ Inhibitors Containing Pyridopyrimidine Scaffold.

Design, Synthesis, and Biological Evaluation of Thieno[3,2‐d]pyrimidine Derivatives As Potential Simplified Phosphatidylinositol 3‐kinase Alpha Inhibitors

Discovery of 2-Methyl-2-(4-(2-methyl-8-(1 H -pyrrolo[2,3- b ]pyridin-6-yl)-1 H -naphtho[1,2- d ]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor Efficacy In Vitro and In Vivo

Structure-based Design, Synthesis and Biological Evaluation of Diphenylmethylamine Derivatives As Novel Akt1 Inhibitors

Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors